Skip to main content
UniHealth

Doctor search

Hala Borno, MD

Internal Medicine · San Francisco

NPI 1528402682

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
3
Since medical school
13 years
Graduated 2013

Offices

3 locations · UCSF Medical Group Business Services · University of California San Francisco

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Borno’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
75.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$44,972

Medicare paid this office $44,972 for 76 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)68$12,448$107

Who their Medicare patients are

76 Original Medicare patients in 2024. Average age 77 · Health risk score 2.35. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.

Conditions among them: Cancer 75% · High blood pressure 70% · Coronary heart disease 33% · Diabetes 30% · Chronic kidney disease 28% · Atrial fibrillation 26% · Depression 17%.

The office billed $557,305, Medicare allowed $59,287 and paid $44,972; for 2,217 services of 17 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024762,217772.35$557,305$44,972
202399916762.78$434,715$43,277
20221121,351752.19$312,084$35,208
2021176499752.24$284,534$39,534
2020168467742.20$298,329$40,303
2019183454752.11$346,022$40,058
2018129197761.94$158,721$20,344

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Long return visit (40+ min)86$18,347$122
Telephone medical discussion with physician, 21-30 minutes16$1,574$87

2022: 4 services

Original Medicare services billed in 2022
Return visit (30+ min)61$5,147$70
Long return visit (40+ min)31$4,193$123
New patient visit (60+ min)17$2,620$154
Telephone medical discussion with physician, 21-30 minutes18$1,588$72

2021: 4 services

Original Medicare services billed in 2021
Return visit (30+ min)142$22,685$80
Long return visit (40+ min)49$6,886$113
New patient visit (60+ min)34$5,085$150
Telephone medical discussion with physician, 21-30 minutes25$2,903$81

2020: 5 services

Original Medicare services billed in 2020
Long return visit (40+ min)102$17,687$99
Return visit (30+ min)107$12,037$70
New patient visit (60+ min)27$4,119$153
Telephone medical discussion with physician, 21-30 minutes30$3,725$70
Return visit (30+ min)14$1,034$65

2019: 3 services

Original Medicare services billed in 2019
Long return visit (40+ min)147$30,332$88
New patient visit (60+ min)50$6,679$134
Return visit (30+ min)24$2,703$66

2018: 3 services

Original Medicare services billed in 2018
Long return visit (40+ min)99$13,981$98
New patient visit (60+ min)35$5,033$144
Return visit (30+ min)15$1,328$70

Drugs they prescribed that Part D paid

$193,142

Pharmacies billed $193,142 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 38) in 2024. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.

15 generic and 23 brand-name prescriptions · $193,142 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Year by year

Part D prescribing by year
202438130% (0)61%$193,142
202312135None19%$419,814
202232564None46%$1,768,112
2021709863% (18)32%$2,277,631
202042383None43%$1,437,466
2019514922% (11)38%$1,698,032
20181434611% (16)None$175,281
20176516NoneNone$1,906
2016297320% (0)None$69,779
2015112200% (0)None$6,971

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 2 drugs

Part D drugs prescribed in 2023
Abiraterone Acetate42$79,206$1,886
Prednisone21$174$8

2022: 8 drugs

Part D drugs prescribed in 2022
Xtandi48$611,780$12,745
Cabometyx21$524,605$24,981
Erleada19$255,739$13,460
Nubeqa11$154,280$14,025
Abiraterone Acetate73$60,140$824
Pradaxa18$9,705$539
Prednisone34$381$11
Levothyroxine18$357$20

2021: 16 drugs

Part D drugs prescribed in 2021
Xtandi49$599,187$12,228
Erleada45$588,368$13,075
Cabometyx13$286,579$22,045
Nubeqa13$161,708$12,439
Lynparza11$161,257$14,660
Abiraterone Acetate140$146,991$1,050
Orgovyx23$51,998$2,261
Eliquis11$5,726$521
Prednisone102$1,222$12
Levothyroxine31$815$26
Dexamethasone22$548$25
Albuterol Sulfate Hfa11$521$47
Gabapentin33$313$9
Amlodipine Besylate16$269$17
Potassium Chloride15$212$14
Atorvastatin13$63$5

2020: 10 drugs

Part D drugs prescribed in 2020
Xtandi48$595,351$12,403
Erleada22$291,770$13,262
Abiraterone Acetate77$253,457$3,292
Zytiga14$147,834$10,560
Lupron Depot12$53,038$4,420
Bicalutamide28$1,177$42
Prednisone57$616$11
Gabapentin22$188$9
Tamsulosin12$163$14
Omeprazole12$82$7

2019: 12 drugs

Part D drugs prescribed in 2019
Zytiga77$863,528$11,215
Xtandi41$462,840$11,289
Abiraterone Acetate38$218,174$5,741
Eliquis11$6,553$596
Bicalutamide40$2,004$50
Prednisone97$1,174$12
Terazosin16$657$41
Oxybutynin Chloride11$482$44
Gabapentin22$244$11
Dexamethasone11$237$22
Ondansetron16$133$8
Tamsulosin11$119$11

2018: 4 drugs

Part D drugs prescribed in 2018
Bicalutamide16$653$41
Terazosin12$182$15
Prednisone19$174$9
Prochlorperazine Maleate12$40$3

2017: 1 drug

Part D drugs prescribed in 2017
Terazosin13$89$7

2016: 4 drugs

Part D drugs prescribed in 2016
Viread11$11,187$1,017
Atorvastatin24$537$22
Benazepril18$146$8
Spironolactone12$117$10

Money from drug and device companies

$1,451 in 2023

Industry payments by year
202322$1,350$1,451
202211$3,000$3,000
202111$1,370$1,370
202022$1,275$1,288
201912None$164

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AlkermesNone$1,350
1 payment
  • Consulting · 2023-04-03 · $1,350
GenzymeJevtana$101
1 payment
  • Meals for Jevtana · 2023-06-03 · $101
See all 2 published payments
Every published payment
GenzymeMeals · 2023-06-03Jevtana$101
AlkermesConsulting · 2023-04-03None$1,350
See earlier years (2022, 2021, 2020, 2019)

2022: $3,000

Payments by company in 2022
PfizerOrgovyx$3,000
1 payment
  • Honoraria for Orgovyx · 2022-10-03 · $3,000

2021: $1,370

Payments by company in 2021
AstraZeneca Pharmaceuticals LPLynparza$1,370
1 payment
  • Consulting for Lynparza · 2021-08-19 · $1,370

2020: $1,288

Payments by company in 2020
E.R. Squibb & Sons L.L.C.None$1,275
1 payment
  • Consulting · 2020-09-02 · $1,275
PfizerInlyta$13
1 payment
  • Education for Inlyta · 2020-10-12 · $13

2019: $164

Payments by company in 2019
AmgenNone$164
2 payments
  • Education · 2019-04-04 · $65
  • Education · 2019-04-04 · $99

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Dendreon Pharmaceuticals LLC · Open- Label Trial of Sipuleucel-T Administered To Active Surveillance Patients for Newly Diagnosed Prostate Cancer Provent · 2019Their institution$10,000

Professional record

NPI
1528402682
Group
UCSF Medical Group Business Services · University of California San Francisco
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Student in a training program (390200000X)
Mailing address
505 Parnassus Ave, Room M987, San Francisco, CA, 94143
NPI first listed
2013-04-19
NPI last updated
2013-04-19

This is when the NPI record was last certified, not a medical board exam.